In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study

Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer

(2011) Elise A. Olsen et al.   JOURNAL OF CLINICAL ONCOLOGY

In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study

(2010) Joshua D. Brody et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma

(2010) Youn H. Kim et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma

(2009) A. Ribas et al.   CLINICAL CANCER RESEARCH

Migration of Skin Dendritic Cells in Response to Ionizing Radiation Exposure

(2009) Ryan J. Cummings et al.   RADIATION RESEARCH

Mechanisms Involved in Radiation Enhancement of Intratumoral Dendritic Cell Therapy

(2008) Seagal Teitz-Tennenbaum et al.   JOURNAL OF IMMUNOTHERAPY

Mycosis fungoides and Sézary syndrome

(2008) Sam T Hwang et al.   LANCET

Dysfunctional DC subsets in RCC patients: Ex vivo correction to yield an effective anti-cancer vaccine

(2008) M. Gigante et al.   MOLECULAR IMMUNOLOGY